Indeed, thyroid dysfunction is the most frequent endocrine irAE and may affect up to 40% of patients receiving ICIs (Baraka et al
Other factors that may contribute to nausea during retatrutide treatment include: Central nervous system effects : GLP-1 receptors are present in brain regions involved in nausea and vomiting, including the area postrema, and activation of these pathways is thought to contribute to the emetogenic effects of this drug class [15] [16] Dose escalation : Rapid increases in dose are more likely to provoke symptoms than gradual titration Individual variability : Genetic, metabolic, and lifestyle factors can influence how sensitive a person is to these effects Dietary habits : Eating large, fatty, or rich meals may worsen nausea in those taking GLP-1-based therapies These mechanisms are not unique to retatrutide and are shared to varying degrees across the entire class of incretin-based medicines
Yet the substantia nigra dopaminergic neuron is also a metabolically stressed cell type whose autonomous activity, calcium handling, and large axonal arbor place unusual demands on linked purposeful movement, reinforcement, and cellular energetic support becomes progressively unstable
When compounded under a physicians supervision and tailored to an individual patients need, GLP-1 preparations continue to be a valid option
Cooking or frying these foods will destroy some of the glutathione they contain
